BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Merck  Sharp  &  Dohme  Limited,  submitted  on  29  June  1998  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for Stocrin (efavirenz). After agreement by the CPMP on 28 January 1998, this medicinal product has 
been referred to Part B of the Annex of the Council Regulation  (EEC) 2309/93, of the 22 July 1993 as 
amended.  
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Prof. R. Gaspar  
Co-Rapporteur: 
Dr. P. Sjöberg 
Licensing status:  
Stocrin  was  not  licensed  in  any  country  outside  or  inside  the  European  Union  at  the  time  of  the 
submission of the application. Stocrin has been licensed in the USA on 17 September 1998. 
2. 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 24 July 1998. 
The  Rapporteur’s  assessment  report  was  circulated  to  all  CPMP  members  on  8  October 
1998.The  Co-Rapporteur’s  assessment  report  was  circulated  to  all  CPMP  members  on  
2 October 1998. 
The draft consolidated list of questions was circulated to all CPMP members on 11 November 
1998 for discussion at the November plenary meeting. The CPMP adopted the consolidated list 
of questions on 19 November 1998. 
The applicant submitted the responses to the CPMP consolidated list of questions to all CPMP 
members on 1 December 1998 and the evaluation restarted at the December CPMP meeting. 
The  joint  Rapporteur/Co-Rapporteur  assessment  report  on  the  responses  to  the  consolidated 
  list of questions was circulated to all CPMP members on 20 January 1999. 
During the meeting in 23 – 24 February 1999, the CPMP agreed on a list of outstanding issues 
to be addressed by the applicant during an oral explanation which was held before the CPMP on 
23 February 1999. In the light of the overall data submitted and the scientific discussion within 
the  Committee,  the  CPMP  issued  by  consensus  a  positive  opinion  for  granting  Marketing 
Authorisation for Stocrin 50, 100 and 200 mg hard capsules on 24 February 1999. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which issued the corresponding Decisions on 28 May 1999. 
1/1
         EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
